^
    Back
    Association details:
    Biomarker:DDR
    Cancer:Non Small Cell Lung Cancer
    Drug:Tecentriq (atezolizumab) (PD-L1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    IASLC-WCLC 2020
    Title:

    OA07.03 - Comutations in DDR Pathways Predict Atezolizumab Response in Non-Small Cell Lung Cancer Patients

    Published date:
    01/12/2021
    Excerpt:
    Comutations in DDR pathways were significantly associated with higher response rate to atezolizumab and improved survival in NSCLC patients. The presence of comutations in DDR pathways could help to identify patients who will benefit from ICIs therapy